Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL
Jordan Gauthier(Seattle Cancer Care Alliance), Cameron J. Turtle(The University of Sydney), David G. Maloney(Fred Hutch Cancer Center), Delaney R. Kirchmeier(Fred Hutch Cancer Center), Aiko Torkelson(Fred Hutch Cancer Center), Qian Wu(Cancer Research Center), Alexandre V. Hirayama(University of Washington), Salvatore Fiorenza, Noam E. Kopmar(University of Washington), Mazyar Shadman(University of Washington), Jenna Voutsinas(Fred Hutch Cancer Center), Carla A. Jaeger-Ruckstuhl(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ryan D. Cassaday(University of Washington), Emily C. Liang(Fred Hutch Cancer Center), Stanley R. Riddell(Fred Hutch Cancer Center), Jennifer J. Huang(Stanford Medicine), Barbara S. Pender, Ryan Basom(Fred Hutch Cancer Center), Kristina Braathen(Fred Hutch Cancer Center), Erik L. Kimble(University of Washington)
Cited by 10
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
|New England Journal of Medicine|1995|1.8k